PHASE 3 EFFICACY AND SAFETY DATA FROM RANDOMIZED, MULTICENTER STUDY OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE) COMPARED WITH TOBI (R) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTION DUE TO PSEUDOMONAS AERUGINOSA